The Food and Drug Administration on Thursday approved a new hemophilia therapy that has the potential to be a more convenient option for some patients and, according to analysts, a lucrative product for its developers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,